Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Chemoprevention trial of contralateral breast cancer with fenretinide. Rationale, design, methodology, organization, data management, statistics and accrual.
De Palo G, Camerini T, Marubini E, Costa A, Formelli F, Del Vecchio M, Mariani L, Miceli R, Mascotti G, Magni A, Campa T, Di Mauro MG, Attili A, Maltoni C, Del Turco MR, Decensi A, D'Aiuto G, Veronesi U. De Palo G, et al. Among authors: campa t. Tumori. 1997 Nov-Dec;83(6):884-94. doi: 10.1177/030089169708300603. Tumori. 1997. PMID: 9526578 Clinical Trial.
Long-term tolerability of fenretinide (4-HPR) in breast cancer patients.
Rotmensz N, De Palo G, Formelli F, Costa A, Marubini E, Campa T, Crippa A, Danesini GM, Delle Grottaglie M, Di Mauro MG, et al. Rotmensz N, et al. Among authors: campa t. Eur J Cancer. 1991;27(9):1127-31. doi: 10.1016/0277-5379(91)90309-2. Eur J Cancer. 1991. PMID: 1835622 Clinical Trial.
Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer.
Veronesi U, De Palo G, Marubini E, Costa A, Formelli F, Mariani L, Decensi A, Camerini T, Del Turco MR, Di Mauro MG, Muraca MG, Del Vecchio M, Pinto C, D'Aiuto G, Boni C, Campa T, Magni A, Miceli R, Perloff M, Malone WF, Sporn MB. Veronesi U, et al. Among authors: campa t. J Natl Cancer Inst. 1999 Nov 3;91(21):1847-56. doi: 10.1093/jnci/91.21.1847. J Natl Cancer Inst. 1999. PMID: 10547391 Clinical Trial.
Tolerability of the synthetic retinoid Fenretinide (HPR).
Costa A, Malone W, Perloff M, Buranelli F, Campa T, Dossena G, Magni A, Pizzichetta M, Andreoli C, Del Vecchio M, et al. Costa A, et al. Among authors: campa t. Eur J Cancer Clin Oncol. 1989 May;25(5):805-8. doi: 10.1016/0277-5379(89)90124-7. Eur J Cancer Clin Oncol. 1989. PMID: 2525470 Clinical Trial.
Can fenretinide protect women against ovarian cancer?
De Palo G, Veronesi U, Camerini T, Formelli F, Mascotti G, Boni C, Fosser V, Del Vecchio M, Campa T, Costa A, et al. De Palo G, et al. Among authors: campa t. J Natl Cancer Inst. 1995 Jan 18;87(2):146-7. doi: 10.1093/jnci/87.2.146. J Natl Cancer Inst. 1995. PMID: 7707390 Clinical Trial. No abstract available.
30 results